| Combination of | |
|---|---|
| Fenofibrate | Fibrate | 
| Simvastatin | Statin | 
| Clinical data | |
| Trade names | Cholib | 
| Routes of administration | By mouth | 
| ATC code | |
| Legal status | |
| Legal status | 
 | 
| Identifiers | |
| CAS Number | |
| KEGG | |
Fenofibrate/simvastatin, sold under the brand name Cholib, is a fixed-dose combination medication used to treat abnormal blood lipid levels when used in combination with a low-fat diet and exercise. [1] It contains fenofibrate and simvastatin. [1]
It was approved for use in the European Union in August 2013. [1]
Fenofibrate/simvastatin is indicated as adjunctive therapy to diet and exercise in high cardiovascular risk adults with mixed dyslipidemia to reduce triglycerides and increase HDL C levels when LDL C levels are adequately controlled with the corresponding dose of simvastatin monotherapy. [1]
{{cite journal}}:  CS1 maint: overridden setting (link)